CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells

(2017) David F. Stroncek et al.   Journal of Translational Medicine

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

(2017) Alec J. Walker et al.   MOLECULAR THERAPY

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

Health conditions associated with metabolic syndrome after cancer at a young age: A nationwide register-based study

(2016) A.E. Kero et al.   Cancer Epidemiology

Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells

(2016) David F. Stroncek et al.   CYTOTHERAPY

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

(2016) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

(2016) Elad Jacoby et al.   Nature Communications

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232

(2015) M. J. Borowitz et al.   BLOOD

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

(2015) H. G. Caruso et al.   CANCER RESEARCH

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

(2015) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study

(2015) Ching-Hon Pui et al.   LANCET ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

(2015) Elizabeth A. Raetz et al.   PEDIATRIC BLOOD & CANCER

Characterization of CD22 expression in acute lymphoblastic leukemia

(2015) Nirali N. Shah et al.   PEDIATRIC BLOOD & CANCER

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

(2015) Patrice Chevallier et al.   Lancet Haematology

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

(2015) P. Chevallier et al.   HAEMATOLOGICA

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

(2014) Michael E. Rytting et al.   CANCER

Declining childhood and adolescent cancer mortality

(2014) Malcolm A. Smith et al.   CANCER

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells

(2014) Keisuke Watanabe et al.   JOURNAL OF IMMUNOLOGY

Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort

(2014) Stefan Essig et al.   LANCET ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia

(2013) Prashant R. Tembhare et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

(2013) Barbara W. Grant et al.   CANCER

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

(2013) Kristian Cibulskis et al.   NATURE BIOTECHNOLOGY

Cognition assessment using the NIH Toolbox

(2013) S. Weintraub et al.   NEUROLOGY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis

(2012) Ron Ram et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases

(2011) Sara Raponi et al.   LEUKEMIA & LYMPHOMA

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Adult acute lymphoblastic leukemia

(2010) Stefan Faderl et al.   CANCER

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

(2010) A. S. Wayne et al.   CLINICAL CANCER RESEARCH

Variables affecting the quantitation of CD22 in neoplastic B cells

(2010) Gregory A. Jasper et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Identification and characterization of fully human anti-CD22 monoclonal antibodies

(2010) Xiaodong Xiao et al.   mAbs

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases

(2008) P Chevallier et al.   LEUKEMIA

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

(2008) K Nguyen et al.   LEUKEMIA